We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serum cytokine profile in pediatric Sweet's syndrome: a case report.
- Authors
Yoshihiko Takano; Hisanori Fujino; Akihiro Yachie; Shin-ichi Sumimoto; Takano, Yoshihiko; Fujino, Hisanori; Yachie, Akihiro; Sumimoto, Shin-Ichi
- Abstract
<bold>Background: </bold>Sweet's syndrome is characterized by fever, leukocytosis, and tender erythematous papules or nodules. It is a rare condition, particularly in the pediatric population, and has recently been proposed to be an autoinflammatory disease that occurs due to innate immune system dysfunction, involving several cytokines, which causes abnormally increased inflammation. To the best of our knowledge, no report has documented the cytokine profile in a pediatric patient with Sweet's syndrome.<bold>Case Presentation: </bold>A previously healthy 34-month-old Japanese girl was hospitalized because of remittent fever and pain in her right lower extremity with erythematous nodules. A skin biopsy of the eruption revealed dermal perivascular neutrophilic infiltration with no evidence of vasculitis, which led to the diagnosis of Sweet's syndrome. She was prescribed with orally administered prednisolone and a prompt response was observed; then, the prednisolone dose was tapered. During treatment she developed upper and lower urinary tract infections, after which her cutaneous symptoms failed to improve despite increasing the prednisolone dosage. To avoid long-term use of systemic corticosteroids, orally administered potassium iodide was initiated, but it was unsuccessful. However, orally administered colchicine along with prednisolone effectively ameliorated her symptoms, and prednisolone dosage was reduced again. We analyzed the circulating levels of interleukin-1β, interleukin-6, interleukin-18, neopterin, and soluble tumor necrosis factor receptors I and II, in order to clarify the pathogenesis of Sweet's syndrome. Of these cytokines, only interleukin-6 levels were elevated prior to orally administered prednisolone therapy. Following therapy, the elevated interleukin-6 levels gradually diminished to almost normal levels; interleukin-1β and interleukin-18 stayed within normal ranges throughout the treatment. Neopterin became marginally elevated after the start of treatment. Both soluble tumor necrosis factor receptor I and soluble tumor necrosis factor receptor II levels increased shortly after the onset of urinary tract infections.<bold>Conclusions: </bold>This is the first case report of pediatric Sweet's syndrome in which serum cytokine levels were investigated. Future studies should gather more evidence to elucidate the pathophysiology of Sweet's syndrome.
- Subjects
BLOOD serum analysis; CYTOKINES; PEDIATRICS; IMMUNOLOGIC diseases; INFLAMMATION; DISEASES in girls; NONSTEROIDAL anti-inflammatory agents; COLCHICINE; GOUT suppressants; PREDNISOLONE; COMBINATION drug therapy; COENZYMES; INTERLEUKIN-1; INTERLEUKINS; URINARY tract infections; TREATMENT effectiveness; SWEET'S syndrome; DIAGNOSIS; THERAPEUTICS
- Publication
Journal of Medical Case Reports, 2017, Vol 11, p1
- ISSN
1752-1947
- Publication type
journal article
- DOI
10.1186/s13256-017-1317-0